ThromboGenics : 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)

Leuven, Belgium - ThromboGenics NV announces that the results from its 2 Year OASIS Phase IIIb study with JETREA® (ocriplasmin) have been published in the renowned AAO Journal Ophthalmology.
Ophthalmology reviewed the OASIS study which was a Phase IIIb randomized, sham controlled, double masked study that followed up patients for 24 months post injection. The study was designed to provide long term controlled efficacy and safety data for JETREA® in patients being treated for symptomatic vitreomacular adhesion (sVMA). The study included 24 months follow up data, the longest period patients have been studied post treatment with this novel medicine.
In its overall conclusion, Ophthalmology confirms 'the OASIS trial demonstrates the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous phase 3 trials with no additional safety signals identified'.
The article 'Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial' can be consulted online here.

Dr Patrik De Haes, CEO of ThromboGenics, said: 'We are pleased that the positive results from this Phase IIIb randomized, controlled trial have now been published in the prestigious AAO Journal Ophthalmology. We are confident that the OASIS data will provide very helpful guidance to the global retina community in their assessment of JETREA® as an effective and safe treatment option for an important group of patients with symptomatic VMA.'
The OASIS study results, including the sub-study read out, will be the subject of various presentations delivered at upcoming US and global retina specialists educational meetings, such as next week's 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in San Francisco, and the Annual Meeting of the American Academy of Ophthalmology (AAO) from the 15thto 18th October in Chicago.